Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Why did Qnexa become Qsymia? diaTribe investigates the thinking behind drug names… and why they’re vital to patient safety.
This month, in a surprise move, Vivus announced that its weight management medication Qsymia is now available via mail order through Walmart. This is an addition to the...
On November 28, CeQur announced that it had received CE Mark approval for its PaQ Insulin Delivery Device , allowing the product to be sold in Europe. The Swiss-based...
In December, Novo Nordisk announced that it will advance FIAsp, an ultra-rapid-acting version of Novolog (insulin aspart), directly into phase 3 trials in late 2013 (the...
In late November, Vivus launched its Get Started! Program , which gives potential users of its weight management medication Qsymia a chance to try the drug free for two...
The past few months have seen the approval of a pair of new drugs designed to treat obesity, Arena’s Belviq (see new now next in diaTribe #44) and Vivus’ Qsymia (see new...
On November 8, an FDA advisory panel voted 8-4 to recommend approval of Novo Nordisk’s ultra-long-acting basal insulin degludec (to be marketed under the name “Tresiba...
(S)he said what?!?
We recently had the opportunity to meet Christopher Angell, the founder and “Chief PWD” (person with diabetes) of GlucoLift. This took place at EASD – that’s the...
The 30th Annual Obesity Society Meeting brings exciting insights on drugs and mobile health.
On August 29, J&J’s chronic pain drug Nucynta ER (tapentadol) was granted FDA approval for the management of the pain associated with diabetic peripheral neuropathy...
On August 17, the FDA approved Mylan’s new generic versions of Actos (pioglitazone), a once-daily oral tablet for the treatment of type 2 diabetes originally sold by...
On September 17, Vivus announced that its obesity medication Qsymia (formerly Qnexa) is now available on the US market – this happened at least several weeks earlier...
A candid interview with diaTribe advisory board member Dr. Anne Peters touches on the newest drugs and devices, curing type 1, and addressing obesity.
As noted in new now next in diaTribe #37, Novo Nordisk announced in October 2011 that it had submitted its two new “next-generation” insulin products for approval in the...
By Hannah Deming Lately, the use of basal insulins (such as Lantus and Levemir) in combination with GLP-1 agonists (such as Byetta , Victoza , and Bydureon ) has been...
Many people with diabetes fear eye diseases leading to blindness. In diabetic macular edema (DME), the leading cause of blindness among working-age Americans (over 560,...
Dr. Arya Sharma highlights the most important weight loss tip everyone should know and why weight maintenance is a major achievement.
In June, pharmaceutical giant Bristol-Myers Squibb (BMS) and its partner AstraZeneca (AZ) acquired the important biotech company Amylin for a cool $7 billion, which we...
On July 17, the FDA approved Vivus’ weight-loss medication Qsymia (formerly called Qnexa), just several weeks after the approval of Arena’s Belviq (see new now next in...

Pages